[Autologous serum and alternative blood products for the treatment of ocular surface disorders]
Related Experiment Video
Updated: Jul 3, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
G Geerling1, J D Unterlauft, K Kasper
1Klinik für Augenheilkunde, Julius-Maximilians-Universität Würzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Deutschland. g.geerling@augenklinik.uni-wuerzburg.de
Abstract:
Eye drops made from autologous serum have been increasingly used in the past decade to treat ocular surface disorders such as persistent epithelial defects and dry eye. Due to biologically active ingredients such as growth factors, vitamins, and nutrients, they can be used to lubricate the ocular surface and support epithelial wound healing. According to current legal requirements, they can be dispensed only for outpatient treatment if the producer has obtained a license from the appropriate local authorities. Therefore, the production and dispensing of autologous serum eye drops in Germany is currently limited to a very few institutions and their patients. We review the current evidence on the use of serum eye drops, recommend a standard protocol for their production, and describe a number of recently emerging alternative blood products for the treatment of ocular surface diseases along with their potential advantages and limitations.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
